---
title: "Pliant Therapeutics Shares Tumble Amid Analyst Downgrades Following Study Suspension"
date: "2025-02-11 00:24:40"
summary: "Pliant Therapeutics shares fell 60% in recent Monday trading after several investment firms downgraded their ratings on the company following its announcement late Friday that it has suspended enrollment and dosing in a phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis. RBC downgraded Pliant to sector perform from outperform..."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Pliant Therapeutics shares fell 60% in recent Monday trading after several investment firms downgraded their ratings on the company following its announcement late Friday that it has suspended enrollment and dosing in a phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis.

RBC downgraded Pliant to sector perform from outperform and cut its price target to $4 from $45, Oppenheimer downgraded the company to perform from outperform, HC Wainwright downgraded it to neutral from buy, Citigroup downgraded it to neutral from buy, with a $4 price target, and Wells Fargo downgraded it to equalweight from overweight, with a $4 price target.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250210:A3313683:0/)
